However, another study reported that a panel of four-biomarkers for early stage ovarian cancer including CA125 in combinations with 16 other biomarkers could achieve a better sensitivity ranging from 92.6% to 96.1% at 98% specificity in comparison to either two or three biomarker panels, when examined using MMC algorithm. Here, MUC16 is linked to ovarian carcinoma.